Indoco Remedies Fair Value
Indoco Remedies (INDOCO) average fair value is ₹437.41 across 5 valuation models — P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF), vs a current market price of ₹204.0 (+114.42%), fair value range ₹0.14–₹1322.02. Examine Indoco Remedies quarterly financials for recent quarterly revenue, profit and EPS trends.
Fair Value Analysis Export
INDOCO Fair Value vs Current Price — Valuation Summary
INDOCO average fair value, fair value range, price gap and valuation status across 5 models: P/B Based Valuation, Dividend Discount Model, Price-to-Sales Valuation, Asset-Based Valuation, Discounted Cash Flow (DCF). See Indoco Remedies P/B ratio trends to compare market price against book value per share.
P/B Based Valuation
Dividend Discount Model
Price-to-Sales Valuation
Asset-Based Valuation
Discounted Cash Flow (DCF)
INDOCO Fair Value Analysis — Data Sources & Coverage
Indoco Remedies financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. For live price and a broader fundamental view, visit Indoco Remedies stock price NSE.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
INDOCO vs Healthcare Sector Peers — P/E, P/B & Market Cap
Indoco Remedies P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Jeena Sikho Lifecare | JSLL | 40.02 | 22.33 | ₹7,891 |
| Accretion Pharmaceuticals | ACCPL | 13.72 | 2.43 | ₹131 |
| Par Drugs & Chemical | PAR | 8.67 | 1.01 | ₹111 |
| Auro Laboratories | AUROLAB | 91.49 | 3.91 | ₹165 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.